---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-258006"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:35:25.179817+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sensei Biotherapeutics cuts workforce 46%, extends cash runway into Q2 2026; Q3 net loss $7.3M

## Summary
- Net loss $7.3M for Q3 2024 vs $7.1M year ago; cash & securities $47.0M as of Sept 30.
- Organizational restructuring: closing Rockville research site, reducing workforce ~46%, focusing on SNS-101.
- SNS-101 Phase 1/2 dose expansion clinical data expected in H1 2025; enrollment ~50% complete.
- Appointed Josiah Craver as SVP Finance, principal financial and accounting officer in September.

## SEC filing metadata
- accession: 0001193125-24-258006
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312524258006/0001193125-24-258006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312524258006/d855965d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-258006
- JSON: https://secwatch.observer/filing/0001193125-24-258006.json
- Plain text: https://secwatch.observer/filing/0001193125-24-258006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.